文献速递消化道肿瘤与早癌肝病

晚期肝细胞癌免疫治疗的替代与改良终点

Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2023-06-01

该研究基于IMbrave150试验中接受阿替利珠单抗联合贝伐珠单抗治疗的279例患者及多中心真实世界免疫治疗队列328例患者的个体水平分析,评估RECIST、mRECIST和imRECIST的客观缓解率及无进展生存期对总生存期的预测价值。结果显示RECIST客观缓解率与总生存期改善相关(IMbrave150:HR 0.24,95%CI 0.17-0.33;真实世界:HR 0.25,95%CI 0.15-0.43),而mRECIST和imRECIST未提供有意义的预测改善。

要点

  • RECIST客观缓解率与免疫治疗肝细胞癌患者的总生存期改善相关。
  • mRECIST和imRECIST客观缓解率未显示更强的总生存期预测能力。
  • RECIST无进展生存期与总生存期仅中度相关,mRECIST或imRECIST未改善此关联。

核心结论

  • RECIST客观缓解率可作为评估新兴治疗的合适信号发现指标。
  • mRECIST和imRECIST未提供有意义的预测总生存期获益的改善。

研究设计与样本

  • 对IMbrave150试验中接受阿替利珠单抗联合贝伐珠单抗治疗的患者进行个体水平事后分析(N=279)。
  • 对多中心真实世界接受免疫治疗的患者队列进行横断面分析(N=328)。

主要发现

  • RECIST客观缓解率与总生存期改善相关(IMbrave150:HR 0.24,95%CI 0.17-0.33;真实世界:HR 0.25,95%CI 0.15-0.43)。
  • mRECIST客观缓解率与总生存期相关(HR 0.30,95%CI 0.22-0.42),imRECIST客观缓解率与总生存期相关(HR 0.36,95%CI 0.30-0.51),但未显示更强的预测能力。
  • RECIST无进展生存期与总生存期仅中度相关,mRECIST或imRECIST未改善此关联。

局限性

  • 对IMbrave150试验的分析为个体水平事后分析。
  • 真实世界分析为横断面分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Immunotherapies have altered the treatment paradigm in HCC. Surrogate and modified endpoints are used to assess early success in clinical studies and guide clinical practice. We sought to determine whether surrogate endpoints and modifications to the conventional criteria for tumor response (RECIST), including modified RECIST (mRECIST) and immune-modified RECIST (imRECIST), are valid measures to predict overall survival (OS) in HCC treated with immunotherapies. APPROACH AND RESULTS: We performed an individual-level post hoc analysis of patients treated with atezolizumab and bevacizumab in the IMbrave150 trial (N = 279) and a cross-sectional analysis of a multicenter real-world patient cohort treated with immunotherapy (N = 328). Landmark analyses showed that objective response rates by RECIST were associated with greater OS including among Child-Pugh A and B patients and among patients treated with immunotherapies in the first- or second-line setting (IMbrave150: HR 0.24, 95% CI, 0.17-0.33; RW: HR 0.25, 95% CI, 0.15-0.43). Objective response rates by mRECIST or imRECIST were not associated with the greater predictive power of OS benefit (mRECIST: HR 0.30, 95% CI, 0.22-0.42; imRECIST: HR 0.36, 95% CI, 0.30-0.51). Progression-free survival determined by RECIST was only moderately correlated with OS, and this association was not improved using mRECIST or imRECIST. CONCLUSIONS: Our results clarify the utility of surrogate and modified endpoints in HCC treated with immunotherapies and support the use of RECIST objective response rates as an appropriate signal-finding measure for the evaluation of emerging treatments. Contrary to their intended purpose, mRECIST and imRECIST did not provide meaningful improvements in predicting OS benefits.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lim M, Muquith M, Miramontes B, et al. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. Hepatology. 2023. PMID: 37254559. doi:10.1097/HEP.0000000000000494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。